Update on Hidradenitis Suppurative (Part II): Treatment.
Although hidradenitis suppurativa is a common and serious skin condition, its treatment is not well established. It is now accepted that the moderate and severe forms of the disease are associated with marked systemic inflammation. The goal of treatment in hidradenitis suppurative is therefore to achieve systemic control of inflammation. In some cases, surgery may also be necessary to reduce the severity of the manifestations of cutaneous inflammation. Recent advances in our understanding of hidradenitis suppurativa have been accompanied by the emergence of novel approaches to its treatment, including the use of certain biologic drugs. Several clinical trials have been undertaken to test the effects of biologics (mainly adalimumab) in this setting. In this review, we analyze the different treatments available for hidradenitis suppurativa.
Servicio de Dermatología, Hospital de Manises, Valencia, España. Electronic address: antmarto@hotmail.com.
A
A
Martorell
Servicio de Dermatología, Hospital Universitario del Sureste, Arganda del Rey, Madrid, España.
F J
FJ
García
Unidad de Gestión Clínica de Dermatología, Hospital Universitario Puerta del Mar , Cádiz, España.
D
D
Jiménez-Gallo
Hospital General de Alicante, Alicante, España.
J C
JC
Pascual
Hospital Virgen del Rocío, Sevilla, España.
J
J
Pereyra-Rodríguez
Complejo Hospitalario de Pontevedra, Pontevedra, España.
L
L
Salgado
Hospital de Santa Creu i Sant Pau, Barcelona, España.
E
E
Villarrasa
D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use; D000068879:Adalimumab / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017577:Cutaneous Fistula / Q000209:etiology / Q000601:surgery; D003622:Dapsone / Q000627:therapeutic use; D017497:Hidradenitis Suppurativa / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab / Q000627:therapeutic use; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D012176:Retinoids / Q000627:therapeutic use
D058891:5-alpha Reductase Inhibitors; D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D007166:Immunosuppressive Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D012176:Retinoids; D003622:Dapsone; D000069285:Infliximab; D000068879:Adalimumab
Acne inversa; Acné inversa; Adalimumab; Biologic therapy; Cirugía; Hidradenitis suppurativa; Hidradenitis supurativa; Surgery; Systemic treatment; Terapia biológica; Terapia sistémica